Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.
The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
Eye & ENT Hospital, Fudan University, Shanghai, Shanghai, China
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
Research Site, Wirral, United Kingdom
Changhua Christian Hospital-Obstetrics and Gynecology ( Site 1203), Changhua County, Changhua, Taiwan
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101), Barcelona, Spain
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104), Madrid, Madrid, Comunidad De, Spain
Shusen Wang, Guangzhou, Gangdong, China
Hunan Cancer Hospital, Hunan, Hunan, China
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.